Integra Lifesciences Holdings (IART) Operating Expenses (2016 - 2025)
Integra Lifesciences Holdings (IART) has disclosed Operating Expenses for 17 consecutive years, with $411.9 million as the latest value for Q4 2025.
- Quarterly Operating Expenses rose 1.2% to $411.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 billion through Dec 2025, up 34.54% year-over-year, with the annual reading at $2.1 billion for FY2025, 34.54% up from the prior year.
- Operating Expenses hit $411.9 million in Q4 2025 for Integra Lifesciences Holdings, up from $390.3 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $928.3 million in Q2 2025 to a low of $320.1 million in Q3 2022.
- Historically, Operating Expenses has averaged $390.2 million across 5 years, with a median of $358.4 million in 2023.
- Biggest five-year swings in Operating Expenses: fell 4.93% in 2022 and later skyrocketed 120.39% in 2025.
- Year by year, Operating Expenses stood at $347.3 million in 2021, then decreased by 4.93% to $330.2 million in 2022, then increased by 9.33% to $361.0 million in 2023, then grew by 12.75% to $407.0 million in 2024, then grew by 1.2% to $411.9 million in 2025.
- Business Quant data shows Operating Expenses for IART at $411.9 million in Q4 2025, $390.3 million in Q3 2025, and $928.3 million in Q2 2025.